{'fraction_non_alphanumeric': 0.0247320692497939, 'fraction_numerical': 0.0032976092333058533, 'mean_word_length': 5.782122905027933, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Engineered atenolol-glycoconjugates to target H9c2 cardiomyocyte cell lines

Background: One of the most important fields of biomedical engineering study nowadays is targeted drug delivery to specific cells. A drug's therapeutic efficacy can be improved and optimised by tightly targeting it to a pathophysiologically essential tissue architecture. The goal of this research is to develop saccharide conjugates for the targeted delivery of Atenolol, a -blocker. 
Methods: Galactose (monosaccharide), pectin (polysaccharide), and chitosan were chosen as the saccharides (polysaccharide). By grafting Atenolol with the modified saccharides, the conjugates were created. Spectroscopic and thermal studies were used to describe the chemically changed saccharides conjugates. H9c2 cell lines were used to conduct drug release research and cellular uptake studies. To investigate cytotoxicity, a brine shrimp lethality test was done. 
Results: The outcomes exhibit that Atenolol-modified saccharide conjugates can productively convey the medication to the target. 
Conclusion: It can be inferred that the improvement of saccharide-drug conjugates can be a compelling methodology for targeting cardiovascular medication.